This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suresh;, G.
Right arrow Articles by Weisman, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suresh;, G.
Right arrow Articles by Weisman, L. E.

PEDIATRICS Vol. 104 No. 4 October 1999, pp. 993-994

IMpact-RSV Study Group Report

The first 20% of the full text of this article appears below.

To the Editor.

The authors of the IMpact-RSV Study Group are to be commended for successfully carrying out the large multicenter trial of palivizumab.1 I wish to offer the following comments regarding the study:

The authors have not stated that education regarding prevention of respiratory syncytial virus (RSV) was done similarly in the treatment and placebo groups. Simple measures like hand-washing and limiting contact with older siblings and adults can reduce RSV transmission. Despite blinding of the nature of the intervention, it is possible that these measures were unevenly distributed in the two groups and led to reduced hospitalization, thereby confounding the effects of palivizumab.

The authors have not . . . [Full Text of this Article]


This article has been cited by other articles:


Home page
 PediatricsHome page
R. Carbajal, V. Biran, R. Lenclen, R. Epaud, P. Cimerman, P. Thibault, D. Annequin, F. Gold, and B. Fauroux
EMLA Cream and Nitrous Oxide to Alleviate Pain Induced by Palivizumab (Synagis) Intramuscular Injections in Infants and Young Children
Pediatrics, June 1, 2008; 121(6): e1591 - e1598.
[Abstract] [Full Text] [PDF]